AngioDynamics (ANGO) earnings
In the quarter ended August 2026, AngioDynamics had revenue of $81M, up 6.9% on a year earlier, and diluted EPS of -0.17.
On October 8, 2026 it reported EPS of -0.04 against an estimate of -0.10 (beat).
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Last | Thu Oct 8, 2026 | Before open | -0.10 | -0.04 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from AngioDynamics's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | $81M | +6.9% | -0.17 | — | -9.0% | 2026-10-08 |
| May 31, 2026 | $87M | +8.0% | — | — | -11.8% | 2026-07-14 |
| Feb 28, 2026 | $78M | +8.9% | -0.19 | — | -16.5% | 2026-04-02 |
| Nov 30, 2025 | $79M | +9.0% | -0.15 | — | -7.7% | 2026-01-06 |
| Aug 31, 2025 | $76M | +12.2% | -0.26 | — | -14.1% | 2025-10-02 |
| May 31, 2025 | $80M | +12.9% | — | — | -7.2% | 2025-07-18 |
| Feb 28, 2025 | $72M | -4.2% | -0.11 | — | -13.9% | 2025-04-02 |
| Nov 30, 2024 | $73M | -7.9% | -0.26 | — | -15.2% | 2025-01-08 |
| Aug 31, 2024 | $67M | -14.2% | -0.31 | -127.0% | -19.4% | 2024-10-03 |
| May 31, 2024 | $71M | -22.1% | — | — | -20.4% | 2024-07-25 |
| Feb 29, 2024 | $75M | -6.9% | -4.67 | — | -265.9% | 2024-04-09 |
| Nov 30, 2023 | $79M | -7.4% | -0.72 | — | -16.6% | 2024-01-08 |
Questions
How did AngioDynamics do last quarter?
In the quarter ended August 2026, AngioDynamics had revenue of $81M, up 6.9% on a year earlier, and diluted EPS of -0.17.
From AngioDynamics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.